Fairvalue-Calculator Fairvalue-Calculator
EN DE

Merdury Biopharmaceutical Corporation (6932) Fair Value & Analysis

Healthcare · TW · Market cap 2.7B TWD

Price6.73 TWD
Fair Value1.58 TWD
Upside-76.5%
Quality95/100
Evidence: Low Range 1.19 TWD – 1.98 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Merdury Biopharmaceutical Corporation (6932) currently trades at 6.73 TWD, while our model-based Fair Value estimate is 1.58 TWD — implying the stock looks roughly 76.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Merdury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development technology platform that integrates drug formulation, 3D powder printing, and hardware and software technologies to create drug-specific 3D printing production equipment, which can be used as a foundation for pharmaceutical companies to provide hosted services and in-house product development. It also offers formulation design and 3D pharmaceutical processing services. Merdury Biopharmaceutical Corporation was founded in 2019 and is headquartered in New Taipei City, Taiwan.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1949% Jiangsu Hengrui Pharmaceuticals Co (600276) -46% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -74% Hansoh Pharmaceutical Group (3692) -47% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Merdury Biopharmaceutical Corporation (6932) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 1.58 TWD versus a price of 6.73 TWD — about −77% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6932?
Our 21-model fair value for Merdury Biopharmaceutical Corporation is 1.58 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 6.73 TWD.
What is the quality score of 6932?
Merdury Biopharmaceutical Corporation has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.